Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40

Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration. Health Serv Res (2012) 0.86

Potentially avoidable inpatient nights among warfarin receiving patients; an audit of a single university teaching hospital. BMC Res Notes (2009) 0.81

Prevention and treatment of venous thromboembolism in patients with cancer. Can Pharm J (Ott) (2012) 0.79

A description of a multistaged professional development course for practising pharmacists in anticoagulation management. Can Pharm J (Ott) (2012) 0.77

Patients' and physicians' satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes (2015) 0.77

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77

Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci (2014) 0.77

Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother (2013) 0.76

Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. Gastroenterology (2016) 0.75

More than Just Chasing INRs: Patient-Centred Care in an Anticoagulation Clinic. Can J Hosp Pharm (2015) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78

Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75

The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet (2010) 3.55

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48

The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21

Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.83

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63

Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med (2013) 2.52

Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50

Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Antiphospholipid syndrome. Lancet (2010) 2.47

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest (2007) 2.32

Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med (2005) 2.32

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31

Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26

Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24

The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21

The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes (2006) 2.20

Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med (2010) 2.19

Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16

A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol (2006) 2.09

Assessment of warfarin dosing requirements after bariatric surgery in patients requiring long-term warfarin therapy. Pharmacotherapy (2013) 2.02

Publication rates of abstracts presented by pharmacy residents at the Western States Conference. Am J Health Syst Pharm (2012) 2.02

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00

Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke (2013) 1.99

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97

Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.97

The consult guys--anticoagulation? Antiplatelet? What's the score? Ann Intern Med (2015) 1.95

Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85

Fresh frozen plasma transfusion in critically ill patients. Crit Care Med (2007) 1.81

Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med (2011) 1.78

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2013) 1.77

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76

Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy (2011) 1.74

Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71

Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J (2003) 1.67

Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67

Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67

Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation (2012) 1.66

Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. Am Heart J (2011) 1.65

Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation (2013) 1.63

Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.63

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol (2008) 1.62

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation (2009) 1.60

Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2002) 1.57

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56

Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation (2014) 1.54

Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54

A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53

Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50

Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47

Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47